claudication

(redirected from Cilostazol)
Also found in: Dictionary, Medical, Legal, Wikipedia.
Graphic Thesaurus  🔍
Display ON
Animation ON
Legend
Synonym
Antonym
Related
  • noun

Synonyms for claudication

disability of walking due to crippling of the legs or feet

References in periodicals archive ?
Methods and Results: To compare prevention by cilostazol and aspirin of progression of atherosclerosis, we conducteda prospective, randomized, open, blinded end point study in 4 East Asian countries.
After the baseline data collection cilostazol was given to the group A while the group B didn't receive cilostazol.
Remnant lipoprotein particles induce apoptosis in endothelial cells by NAD(P)H oxidase-mediated production of superoxide and cytokines via lecitin-like oxidized low-density lipoprotein receptor-1 activation: prevention by cilostazol.
Potentially, drugs designed to relax and dilate the walls of blood vessels, such as cilostazol (Pletal), may be recommended to ease the pain of walking.
Sutariya, "Preparation and characterization of microemulsion of cilostazol for enhancement of oral bioavailability," Current Drug Delivery, vol.
20 Takayuki Matsumoto, Tsuneo Kobayashi, Kentaro Wakabayashi and Katsuo Kamata; Cilostazol improves endothelium-de- rived hyperpolarizing factor-type relaxation in mesenteric arteries from diabetic rats, Am J Physiol Heart CircPhys- io,2005;H1933-H1940
CILOSTAZOL (PLETAL): is an antiplatelet drug with vasodilatation properties; it is approved for use in intermittent claudication where there is no pain at rest and no tissue necrosis.
Population pharmacokinetic analysis of cilostazol in healthy subjects with genetic polymorphisms of CYP3A5, CYP2C19 and ABCB1.
There have also been reports about improvement of apathy and cognitive function after stroke by treatment with cilostazol (33).
18] 5 [micron]m; 4,6 x 250 mm LC-MS/MS ELL/ 250 [micron]L Atlantis (ESI modo Cilostazol [C.
If you have severe pain or cramping in your legs when you walk, your health care professional may recommend clopidogrel (Plavix), cilostazol (Pletal) or pentoxifylline (Trental).
The only two drugs currently approved in the United States for this indication, pentoxifylline and cilostazol, are reported to increase walking distance by 15% and 25%, respectively.
Their topics include cilostazol and dipyridamole: much more than weak inhibition of platelets, unfractionated heparin and low molecular weight heparin in ischemic heart disease, vitamin K antagonists, anti-thrombotic strategies in patients undergoing elective percutaneous coronary interventions, and anti-thrombotic therapy in venous thrombosis and pulmonary embolism.
This effect of cilostazol was not seen in non-carriers of the loss-of-function polymorphism.